Bacground and Aims: To identify and well-characterize the prevalence of hepatitis C virus infection in different populations in Yemen. Also, to determine the future epidemiological study areas in Yemen. Materials and Methods: A systematic review was conducted with the use of the PRISMA guidelines. Between 1980 to 2020, a comprehensive search was done for any epidemiological data on hepatitis C in Yemen that were conducted in each PubMed, web of Science, Scopus, and Google Scholar. Results: Forty-nine (49) studies were matching the inclusion and exclusion criteria from the four databases. After analyzing these 49 studies we found that in the general group of the population the prevalence was ranged between 0.07%-8.5%. Where the highest prevalence was in pregnant women (up to 8.5%) then the public (up to 6%) then blood donors and children up to 3% and 2.8% respectively. In the intermediate-risk group, hepatitis C virus infection prevalence was ranged between 1.03%-3.5% where all population was from the health department workers. In the high-risk group, the range was between 6.4%-62.7%, and the highest prevalence was recorded in liver disease patients. In the patient’s group the range of hepatitis C virus infection prevalence was between 0%-46%, while the sickle cell anemia patients were the lowest prevalence the chronic renal failure patients had the highest prevalence. Conclusion: This systemic review demonstrates a high prevalence of hepatitis C infection in Yemen. There is also a need to expand the scope of research and pay attention to new research groups and other cities to get a more comprehensive idea of the prevalence of the hepatitis C virus in Yemen.
Giriş ve Amaç: Yemen’deki farklı popülasyonlarda hepatit C virüsü enfeksiyonunun prevalansını belirlemek, iyi karakterize etmek ve ayrıca, Yemen’de gelecekteki epidemiyolojik çalışma alanlarını belirlemektir. Gereç ve Yöntem: PRISMA yönergelerinin kullanımıyla sistematik bir inceleme yapıldı. Yemen’deki hepatit C ile ilgili; PubMed, web of Science, Scopus ve Google Scholar’da 1980 ile 2020 arasında yürütülen, herhangi bir epidemiyolojik veri için kapsamlı bir araştırma yapıldı. Bulgular: Kırk dokuz (49) çalışma, dört veri tabanındaki dahil etme ve dışlama kriterleriyle eşleşti. Bu 49 çalışmanın analizi ile nüfusun genel grubunda prevalansın %0.07-%8.5 arasında değiştiğini bulduk. En yüksek prevalansın hamile kadınlarda olduğu (%8.5’e kadar), ardından genel (%6’ya kadar), ardından da sırasıyla %3 ve %2.8 ile kan bağışçıları ve çocuklarda olduğu görüldü. Orta risk grubunda, tüm popülasyon sağlık departmanı çalışanlarından olmak üzere, hepatit C virüsü enfeksiyonu prevalansı %1.03-3.5 arasında değişiyordu. Yüksek riskli grupta, prevalans aralığı %6.4-%62.7 arasında olup, en yüksek prevalans karaciğer hastalığı olanlarda kaydedilmiştir. Hasta grubunda hepatit C virüsü enfeksiyonu prevalansı aralığı %0-%46 arasındayken, orak hücreli anemili hastalar en düşük prevalansa, kronik böbrek yetmezliği olan hastalarsa en yüksek prevalansa sahipti. Sonuç: Bu sistemik derleme, Yemen’deki hepatit C enfeksiyonu prevalansının yüksek olduğunu göstermektedir. Yemen’deki hepatit C virüsünün prevalansı hakkında daha kapsamlı bir fikir edinmek için araştırma kapsamını genişletmeye ve yeni araştırma gruplarına ve diğer şehirlere dikkat etmeye ihtiyaç vardır.
1. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol 2018;6:79-84.
2. Organization WH. Hepatitis C: fact sheet 27 July 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis- c#:~:text=Key%20facts,major%20cause%20of%20liver%20 cancer.
3. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-8.
4. Chemaitelly H, Mahmud S, Mumtaz GR, et al. Hepatitis C virus in the Middle East and North Africa: its epidemiology and the way forward In: Laher I, ed. Handbook of Healthcare in the Arab World. New York, NY: Springer International Publishing; 2019:1‐27.
5. Organization WH. Global Hepatitis Report 2017: World Health Organization; 2017.
6. D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol 2017;24:31-7.
7. Organization WH. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization, 2016.
8. Organization WH. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. World Health Organization, 2016.
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-e34.
10. Houghton M. Discovery of the hepatitis C virus. Liver Int 2009;29:82- 8.
11. Amran OAA, Al-Shamahy HA, Al Hadad AM, Jaadan BM. Explosion of hepatitis B and C viruses among hemadialysis patients as a result of hemodialysis crisis in Yemen. Universal Journal of Pharmaceutical Research 2019. DOI: 10.22270/ujpr.v4i5.311.
12. Scott DA, Constantine NT, Callahan J, et al. The epidemiology of hepatitis C virus antibody in Yemen. Am J Trop Med Hyg 1992;46:63-8.
13. el Guneid AM, Gunaid AA, O’Neill AM, et al. Prevalence of hepatitis B, C, and D virus markers in Yemeni patients with chronic liver disease. J Med Virol 1993;40:330-3.
14. Gray GC, Kassira EN, Rodier GR, et al. Remote village survey for agents causing hepatosplenic disease in the Republic of Yemen. Trop Doct 1999;29:212-9.
15. Al-Moslih MI, Al-Huraibi MA. Prevalence of hepatitis C virus among patients with liver disease in the Republic of Yemen. East Mediterr Health J 2001;7(4-5):771-8.
16. Sallam TA, Tong CYW, Cuevas LE, et al. Prevalence of blood-borne viral hepatitis in different communities in Yemen. Epidemiol Infect 2003;131(1):771-5.
17. Sultan A, Abdulrahman A, Omar S, Huda S. Short communication the frequency of hepatitis B and C among blood donors: a hospital-based study in Sana’a, Yemen. Biohealth Science Bulletin 2010;2:65-68.
18. Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl 2010;21(6):1165-8.
19. Al-Shamiri AH, Al-Taj MA, Ahmed AS. Prevalence and co-infections of schistosomiasis/hepatitis B and C viruses among school children in an endemic areas in Taiz, Yemen. Asian Pac J Trop Med 2011;4:404-8.
20. Saghir SAM, Al-Hassan FM, Alsalahi OSA, Alhariry A, Baqir HS. Frequencies of HBV, HCV, HIV, and syphilis markers among blood donors: A hospital-based study in Hodeidah, Yemen. Trop J Pharm Res 2012;11:132-6.
21. Alodini AQ. Prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections among blood donors at Al-Thawra Hospital Sana’a City-Yemen. Yemeni J Med Sci 2014;6:16-20.
22. Al-Waleedi AA, Khader YS. Prevalence of hepatitis B and C infections and associated factors among blood donors in Aden City, Yemen. East Mediterr Health J 2012;18:624-9.
23. Gacche RN, Kaid AM. Epidemiology of viral hepatitis B and C infections in ibb city, Yemen. Hepat Mon 2012;12:460-2.
24. Gacche RN, Al-Mohani SK. Seroprevalence and risk factors for hepatitis C virus infection among general population in central region of Yemen. Hepat Res Treat 2012;2012:689726
25. Murad EA, Babiker SM, Gasim GI, et al. Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana’a, Yemen. BMC Pregnancy Childbirth 2013;13:127.
26. Al-Nabehi BAH, Al-Shamahy H, Saeed WSE, Musa AM, El Hassan AM, Khalil EAG. Sero-molecular epidemiology and risk factors of viral hepatitis in urban Yemen. International Journal of Virology 2015; 11:133-8.
27. Al-Zubiery T, Alharazi T, Alsumairy H, Al-Zubiery A. Sero-prevalence of Hbs Ag, HCV and HIV Among Blood Donors in Three Blood Bank Centers in Sana’a City: Yemen. Journal of Biotechnology and Biomedical Science 2017;1:46-52.
28. Al-Zubiery TK, Alharazi T, Alsumairy H, et al. Sero-prevalence of Anti-HCV among Yemenis blood donors attending national blood transfusion and research centre in Sana’a: Yemen. International Blood Research & Reviews 2017;7:1-6.
29. Al-Kadassy AM, Balkam FA, Bashanfer S. Seroprevalence of Hepatitis B and C Infections among Adult Males in Beit al-Faqih District, Al-Hodeidah Governorate, Republic of Yemen. Journal of Advances in Medicine and Medical Research 2016;19:1-6.
30. Al-Hatheq A, Abakar AD, Al-Ofairi B. Seroprevalence of hepatitis C virus infection among blood donors and clinical visitors in Amran Governorate, Yemen. International Journal of Molecular Microbiology 2019;2:25-33.
31. Ghaleb YA, Alshahari AZ, Ali MA, et al. Prevalence and associated factors with transfusion-transmitted infections among blood donors at the national blood transfusion and research center, Sana’a, Yemen. 2020. DOI: 10.21203/rs.3.rs-116777/v1
32. Barkat B, Naseeb AA. Sero-prevalence and associated factors of viral hepatitis B and C infection among pregnant women in Alaeen Valley, Hadhramout Governorate, Yemen: Al-Razi University; 2020.
33. Shidrawi R, Al-Huraibi MA, Al-Haimi MA, et al. Seroprevalence of markers of viral hepatitis in Yemeni healthcare workers. J Med Virol 2004;73:562-5.
34. Al-Kebsi A, Othman A, Abbas A, et al. Sero-prevalence of hepatitis C virus among dental clinic workers in Sana’a city-Yemen and the risk factors contributing for its infection. Univ J Pharm Res 2017;2:28-33.
35. Al-Marrani WHM, Al-Shamahy HA. Prevalence of HBV and HCV; and their associated risk factors among public health center cleaners at selected Public Health Centers in Sana’a city-Yemen. Journal of Pharmaceutical Research 2018;3:58-62.
36. Gunaid AA, Nasher TM, el-Guneid AM, et al. Acute sporadic hepatitis in the Republic of Yemen. J Med Virol 1997;51:64-6.
37. Al-Selwi AHA, Elezzy Y, Al Ghazali J, Hadi S. Association of hepatocellular carcinoma with hepatic viral markers B and C among Yemenis patients at Althawra Hospital Sana’a. Sudan Medical Journal. 2009;4:237-42.
38. Salem A. Bin Selm , Prevalence of hepatitis B and C viral markers in chronic liver disease patients: a single center experience from Yemen. Arab J Gastroenterol 2010;11:105-7.
39. Bin Selm SA. The seroprevalence of anti-HCV in high-risk dialysis patients. Saudi J Kidney Dis Transpl 2011;22:806-7.
40. Saeed NM, Bawazir AA, Al-Zuraiqi M, et al. Why is hepatocellular carcinoma less attributable to viral hepatitis in Yemen? Asian Pac J Cancer Prev 2012;13:3663-7.
41. Salem A, Abdulrab A, Alfakeh Y, Aown A. Hepatocellular carcinoma in Yemeni patients: a single centre experience over an 8-year period. East Mediterr Health J 2012;18:693-9.
42. Baghza NM. The prevalence of hepatitis C virus among hemodialysis patients in Yemen. J Purity Utility React Environ 2014;3:62-6.
43. Aman K, Al-Dubai SA, Aman R, Hawash A, Alshagga M, Kassim S. Prevalence and associated factors of hepatitis C virus infection among renal disease patients on maintenance hemodialysis in three health centers in Aden, Yemen: a cross sectional study. Saudi J Kidney Dis Transpl 2015;26:380-5.
44. Al-Haimi M, Hamid GA, Ahmed AS. Hepatocellular carcinoma in Yemen: Epidemiology and clinical presentation. World Journal of Pharmaceutical and Medical Research 2018;4:248-53.
45. Gaballah A, Shawky S, Elsawaf G, et al. Virological Profiles of HBV and HCV in Hepatocellular Carcinoma in Egypt and Yemen. Egyptian Journal of Medical Microbiology 2018;27:7-17.
46. Hanash SH, Al-Shamahy HA, Bamshmous MHS. Prevalence and genotyping of hepatitis C virus in hemodialysis patients and evaluation of HCV-core antigen test in screening for dialysis in Sana’a city, Yemen. Universal J Pharm Res 2019;4:14-8.
47. Al-Yousofi MAQ. Prevalence of hepatitis B and C virüs among hemodialysis patient and infection control in dialysis units in Sana’a City, Yemen. Al-Razi University; 2019.
48. Almezgagi M, Edrees W, Al-Shehari W, et al. Prevalence of hepatitis B virus and hepatitis C virus and associated risk factors among hemodialysis patients in Ibb city-Yemen. PSM Microbiol 2020;5:32- 40.
49. Denis F, Aussel L, Ranger S, et al. Prevalence of antibodies to hepatitis C virus among patients with leprosy in several African countries and the Yemen. J Med Virol 1994;43:1-4.
50. Salem AK. Prevalence of HCV among Yemeni patients with non-Hodgkin’s lymphoma at AI-Thawra teaching hospital. Gulf J Oncolog 2009(5):22-9.
51. Al-Mansoob AS, Salem AK, A-Selwi A, Assamawi A. Risk factors of hepatitis B and C viruses among patients admitted in surgical departments at Al-Thawra Hospital, Sana’a, Yemen. Sudan Medical Journal 2013;49:168-75.
52. Thabet HM, AL-Souraqy AM, Abbas AH, AL-hogary IQ, Anam EN, Noaman NS. The relationship of Hepatitis C and B with diabetes of Yemeni patients. Asian Pac J Health Sci. 2014;1(4):370-6.
53. Al-Hegami MA, Al-Mamari A, Al-Kadasse AS, et al. Prevalence and risk factors of hepatitis B and hepatitis C virus infections among patients with chronic renal failure in Zabeed city, Yemen Republic. Open Journal of Medical Microbiology 2015;5:136-42.
54. Al Awfi MS, Al-Kamarany MA, Mohsen R, et al. Hepatitis C Virus Infection among Chronic Renal Failure Patients Pre–Dialysis Therapy in Hodiedah City, Yemen. Microbiology Research Journal International. 2017:1-6.
55. Al-kadassy AM, Alkadasi MN, Puttauah E, Naji A, Alhwthyf A. Prevalence of hepatitis B, C and HIV among sickle cell disease patients in Hodeidah city, YEMEN. J Bio Innov 2018;1:114-25.
56. Ghanem YA, Al-Rabeei NA. Prevalence of Hepatitis B and C Viral Infection among Patients Attending to the Endoscopic Clinic at Al-Thowrah Hospital in Sana’a City, Yemen. Global Journal of Gastroenterology & Hepatology. 2018;6:1-4.
57. Nagi A. ALHaj SMA-A, Khaldoon S. Abdullah, Abdul Baki, Al-Robasi. Prevalence and risk factors of hepatitis C virus infection among lymphoma patients in Sana’a cıty, Yemen. Global journal for Research Analysis 2018;7:31-3.
58. Al-Shaer MY, Bamashmus MA, Al-Akily SA, Al-Akhlee HA. Prevalence of hypertension, diabetes mellitus and Hepatitis B and C among people seeking cataract surgery in eye camps in Yemen. Yemeni J Med Health Res. 2019;8:54-61.
59. Bamashmus MA, Abdulrahim AM. Frequency of Hepatitis B, Hepatitis C and Human Immunodeficiency virus in patients undergoing cataract surgery. Hadhramout University Journal of Natural & Applied Sciences 2019;169-15.
60. Singh MN, Lal A, Poddar CK, Ejaz SK. Comparative evaluation of ELISA and rapid screening techniques for the diagnosis of HCV in haemodialysis patients in tertiary care hospital, South Bihar, India. Journal of Evolution of Medical and Dental Sciences 2017;6:6683- 7.
61. Chaabna K, Cheema S, Abraham A, et al. Systematic overview of hepatitis C infection in the Middle East and North Africa. World J Gastroenterol 2018;24:3038-54.
62. Botheju WSP, Zghyer F, Mahmud S, et al. The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses. Sci Rep 2019;9:1-15.
63. Chemaitelly H, Chaabna K, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Fertile Crescent: systematic review and meta- analysis. PloS One 2015;10:e0135281.
64. Hassan-Kadle MA, Osman MS, Ogurtsov PP. Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study. World J Gastroenterol 2018;24:3927-57.
65. Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta- analyses, and meta-regressions. Sci Rep 2018;8:1661.
66. Harfouche M, Chemaitelly H, Mahmud S, et al. Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta- regressions. Epidemiol Infect 2017;145:3243-63.
67. Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World J Gastroenterol 2017;23:151-66.
68. Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95:939-47.
69. Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int J Infect Dis 2016;46:116-25.